MedTrace Logo

Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections

NCT04933344 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1130

Last updated 2022-05-06

No results posted yet for this study

Summary

the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection

Conditions

  • Dactinomycin Adverse Reaction
  • Bone and Joint Infection

Interventions

OTHER

patients having had BJI or PJI treated with daptomycin

patients having had BJI or PJI treated with daptomycin who developped an adverse event : eosinophilic pneumonia and/or elevation of CPK

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2022-03-01
Completion
2022-07-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04933344 on ClinicalTrials.gov